IDT: Good Medicine
IDT: Good Medicine. Under new management IDT is shifting its focus from contract manufacture of pharmaceuticals to more in house development. The acquisition of a portfolio of generic drugs from a global generics company will see IDT capture significantly higher margin than it currently does as a supplier of APIs. The next 18 months will see revenue grow and the business move to profitability. We initiate with an ADD recommendation and a DCF valuation and price target of A$0.37. Full report here: (VIEW LINK)
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
No areas of expertise